Media Centre
Latest press releases
-
Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer
-
Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive at three years
-
Enhertu granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
-
AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU
-
AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against ‘undruggable’ targets
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director, Global Media Relations (Corporate)
+44 (0)1223 344 800
Angela Fiorin
Director, Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Chris Calland
Director, Global Media Relations (Oncology)
+44 (0)1223 344 800
Fiona Cookson
Director, Global Media Relations
(COVID-19 vaccine)
+44 (0)1223 344 800
Sinead Keller
Director, Global Media Relations
(COVID-19 vaccine)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
Brendan McEvoy
Head, US External Communications
+1 302 885 2677
Lisa Taylor
Senior Director, Corporate Communications (Alexion)
+1 857 338 9025
Amanda Talamonte
Manager, Global Media Relations
+44 (0)1223 344 800
Flavia Garcia
Manager, Global Media Relations
+44 (0)1223 344 800
